Abstract:Background Systemic sclerosis (SSc) is a connective tissue disease characterized by autoimmunity, small vessel vasculopathy and excessive collagen deposition in the skin and internal organs. Pulmonary involvement is responsible for reducing the functional capacity to exercise and represents the main cause of death. The six-minute walk test (6MWT) is a simple, non-invasive, easy-to-perform, and reliable submaximal aerobic exercise test that can used in patients with advanced lung disease. Patients with SSc often have not only lung disease, but combinations of cardiopulmonary involvement, skin fibrosis, musculoskeletal damage, and joint disease, which can confound the 6MWT interpretation. As it is an independent predictor of SSc-related mortality, the 6MWT is a potentially useful tool in the assessment of outcomes along with pulmonary function tests (PFTs) and computed tomography. Currently, there is a huge concern about the need for early screening, search for new treatments and closer monitoring of patients with diffuse cutaneous systemic sclerosis-associated interstitial lung disease (dcSSs-ILD) before irreversible deterioration of lung function occurs. Objectives To build a predictive model for the six-minute walk distance (6MWD) in women with dcSSs-ILD without pulmonary arterial hypertension. Methods This is a cross-sectional study in which 69 women with dcSSs-ILD underwent the 6MWT, Health Assessment Questionnaire-Disability Index (HAQ-DI), PFTs (including spirometry, measurement of pulmonary diffusion capacity for carbon monoxide-DLCO and measurement of respiratory muscle strength), handgrip strength (HGS) and quadriceps strength (QS). Results The mean 6MWD was 447 ± 78 m, with 43.5% of the participants not reaching 80% of the predicted value. The 6MWT was positively correlated with HR (r = 0.418, P = 0.0004), forced vital capacity (r = 0.306, P = 0.011), DLCO (r = 0.360, P = 0.002), maximal inspiratory pressure (r = 0.268 , P = 0.029), and maximal expiratory pressure (MEP, r = 0.288, P = 0.019) and negatively with age (r = -0.378, P = 0.001), body mass index (BMI) r = -0.248, P = 0.039) and HAQ-DI (r = -0.438, P = 0.0001). In the multiple linear regression analysis, QS, BMI, DLCO, age and MEP explained 72% of the 6MWD variability. Conclusion In patients with dcSSs-ILD, alongside reduced pulmonary diffusion, deterioration in respiratory and peripheral muscle strength negatively impact performance during the 6MWT. Furthermore, the greater the age and BMI, the lower the 6MWD. Our results are promising and may become a contribution to future investigations aimed at new pharmacological therapies for dcSSs-ILD. Implications These findings may help the growing number of randomized controlled trials that have emerged in search of disease-modifying therapies for dcSSs-ILD, with the aim of incorporating the 6MWD as a clinical outcome measure.

Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study

Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease

Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Use of 6-Minute Walk Test for Assessing Severity of Interstitial Lung Disease: an Observational Study.

Study of relationship between six-minute walk test and lung function and quality of life for patients with chronic obstructive pulmonary disease

Exercise intolerance and oxygen dynamics in nontuberculous mycobacteria with bronchiectasis

The 6-min walking distance: long-term follow up in patients with COPD

Alterations in stride-to-stride fluctuations in patients with chronic obstructive pulmonary disease during a self-paced treadmill 6-minute walk test

Features and predictive value of 6-min walk test outcomes in interstitial lung disease: an observation study using wearable monitors

Six-Minute Walking Test in Patients with Chronic Obstructive Pulmonary Disease

VARIABILITY OF 6-MINUTE WALK DISTANCE IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis

Relationship between six-minute walk distance and cardiopulmonary exercise testing in non-obstructive hypertrophic cardiomyopathy

Prognostic Value of Borg Scale Following Six-minute Walk Test in Hospitalized Older Patients with Heart Failure

Use of 6-min walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases

Long-term effect of non-severe COVID-19 on pulmonary function, exercise capacities and physical activities: a cross-section study in Sakaka Aljouf

Exercise Intolerance In Long Covid After 26 Months From Severe Acute Disease

Changes Observed in the 6-minute Walk Test in Response to Exercise-based Cardiac Rehabilitation

Correlation of Six-Minute Walk Test and COPD Assessment Test (CAT) Scores with Spirometric Indices in Chronic Obstructive Pulmonary Disease Patients

Use of 6‐minute walk distance to predict lung transplant‐free survival in fibrosing non‐IPF interstitial lung diseases

Prediction of Poor Short-Term Prognosis and Unmet Needs in Advanced Chronic Obstructive Pulmonary Disease: Use of the Two-Minute Walking Distance Extracted from a Six-Minute Walk Test